A Better Treatment for Advanced-Stage Hodgkin’s Lymphoma?
Mené sur 1 334 patients atteints d'un lymphome hodgkinien de stade III ou IV (durée médiane de suivi : 73 mois), cet essai randomisé évalue l'efficacité, du point de vue de la survie globale, et la toxicité du brentuximab védotin (un conjugué anticorps-médicament ciblant CD30) en ajout à une chimiothérapie de type AVD (doxorubicine, vinblastine et dacarbazine) par rapport à une chimiothérapie de type ABVD (doxorubicine, bléomycine, vinblastine et dacarbazine)
Treatment for patients with Hodgkin’s lymphoma is one of the success stories of modern medicine. A once uniformly fatal disorder is now curable, even in an advanced stage, in the great majority of patients. In fact, particularly in limited-stage Hodgkin’s lymphoma, much of the therapeutic focus is on maintaining the high probability of cure while reducing the incidence of toxic effects. How little therapy can we give without losing efficacy? For patients with advanced-stage, high-risk disease, debates regarding the best currently available approach have centered on the “old standard” ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen,1 the very intensive escalated (....)
New England Journal of Medicine , éditorial, 2021